UK clinical guideline for the prevention and treatment of osteoporosis
CL Gregson, DJ Armstrong, J Bowden, C Cooper… - Archives of …, 2022 - Springer
Abstract Summary The National Osteoporosis Guideline Group (NOGG) has revised the UK
guideline for the assessment and management of osteoporosis and the prevention of …
guideline for the assessment and management of osteoporosis and the prevention of …
Secondary osteoporosis
PR Ebeling, HH Nguyen, J Aleksova… - Endocrine …, 2022 - academic.oup.com
Osteoporosis is a global public health problem, with fractures contributing to significant
morbidity and mortality. Although postmenopausal osteoporosis is most common, up to 30 …
morbidity and mortality. Although postmenopausal osteoporosis is most common, up to 30 …
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
F Cardoso, S Kyriakides, S Ohno… - Annals of …, 2019 - annalsofoncology.org
In 2018, the predicted number of new breast cancers in 28 European Union (EU) countries
was 404 920, with estimated age-adjusted annual incidence of breast cancer of 144.9/100 …
was 404 920, with estimated age-adjusted annual incidence of breast cancer of 144.9/100 …
Bone metastasis: mechanisms, therapies, and biomarkers
Skeletal metastases are frequent complications of many cancers, causing bone
complications (fractures, bone pain, disability) that negatively affect the patient's quality of …
complications (fractures, bone pain, disability) that negatively affect the patient's quality of …
[HTML][HTML] Bone health in cancer: ESMO clinical practice guidelines
Highlights•The clinical course of advanced cancer for many patients with bone metastases
can be transformed through optimum multidisciplinary management.•Bone-targeted agents …
can be transformed through optimum multidisciplinary management.•Bone-targeted agents …
[HTML][HTML] Menopausal osteoporosis: screening, prevention and treatment
EL Yong, S Logan - Singapore medical journal, 2021 - ncbi.nlm.nih.gov
Screening for osteoporosis in women can be based on age and weight, using the
Osteoporosis Screening Tool for Asians and assessment for other risk factors such as early …
Osteoporosis Screening Tool for Asians and assessment for other risk factors such as early …
Management of osteoporosis in survivors of adult cancers with nonmetastatic disease: ASCO clinical practice guideline
CL Shapiro, C Van Poznak, C Lacchetti… - Journal of Clinical …, 2019 - ascopubs.org
PURPOSE The aim of this work is to provide evidence-based guidance on the management
of osteoporosis in survivors of adult cancer. METHODS ASCO convened a multidisciplinary …
of osteoporosis in survivors of adult cancer. METHODS ASCO convened a multidisciplinary …
RANKL/RANK/OPG system beyond bone remodeling: involvement in breast cancer and clinical perspectives
Abstract RANKL/RANK/OPG system consists of three essential signaling molecules: i) the
receptor activator of nuclear factor (NF)-kB-ligand (RANKL), ii) the receptor activator of NF …
receptor activator of nuclear factor (NF)-kB-ligand (RANKL), ii) the receptor activator of NF …
Long-term endocrine and metabolic consequences of cancer treatment: a systematic review
The number of patients surviving≥ 5 years after initial cancer diagnosis has significantly
increased during the last decades due to considerable improvements in the treatment of …
increased during the last decades due to considerable improvements in the treatment of …
Aromatase inhibitor-associated musculoskeletal syndrome: understanding mechanisms and management
T Hyder, CC Marino, S Ahmad… - Frontiers in …, 2021 - frontiersin.org
Aromatase inhibitors (AIs) are a key component in the chemoprevention and treatment of
hormone receptor-positive (HR+) breast cancer. While the addition of AI therapy has …
hormone receptor-positive (HR+) breast cancer. While the addition of AI therapy has …